Key Takeaways
- Flat quarter, GST-driven: Revenue of ₹74.5 crores was largely flat year-on-year as the GST rate transition to 5% temporarily disrupted channel inventory in September, prompting the company to offer extended credit and discounts.
- H1 profitability held up: Despite the Q2 top-line stall, first-half PAT rose ~39% and the ₹160 crore cash balance was maintained even after a ~₹17 crore dividend payout.
- Dydrogesterone drag masks underlying growth: A strategic decision to shrink a once-₹40 crore brand to ₹10 crores over 24 months has eaten away gains from the rest of the portfolio, making headline growth look weaker than the base business.
- New COO is the bet on field-force productivity: Amrut Medhekar joins with a mandate to fix MR productivity, a long-acknowledged weakness where management sees high operating leverage if sales growth accelerates without adding headcount.
- What to watch next quarter: Whether the promised H2 rebound materialises now that GST disruption is behind, and the aspirational growth plan management said it would share in a few weeks.
The GST Transition & Quarter Mechanics
- Rate cut, channel disruption: The GST rate on relevant products moved from 12% or 18% to a flat 5% in September, leaving channel partners holding higher-tax-paid inventory. Jagsonpal cushioned the impact by offering an extra 30 days' credit on September sales and a 1% additional discount for advance payments, which moderated the quarter's revenue.
- Pass-through with no structural damage: MRPs came down with the rate cut but the change is a pass-through with no net impact on the company. The inverted duty structure (inputs at 18%, output at 5%) is not material given gross margins and available GST credits.
- Logistics compounded the softness: Prolonged monsoons, flooding in Punjab, and a 15-day shutdown in Assam added operational friction unrelated to GST.
- Market backdrop was already sluggish: The Indian pharma market grew ~7.5% in Q2, driven by price and new launches with negligible volume growth. Jagsonpal's therapy areas grew much slower at 2.5% to 3%.
Manish Gupta: "I believe India is not one market but multiple markets. And so there is a place for trade generics. The customer base for trade generics is different so also for Jan Aushadhi."
Portfolio Dynamics & the Dydrogesterone Overhang
- The ₹30 crore headwind: Dydrogesterone scaled from zero to ₹40 crores in 18 months, then was deliberately wound down to ₹10 crores over the subsequent 24 months as market conditions shifted. That ₹30 crore decline has been absorbing growth from the rest of the portfolio, making overall performance look weaker than the underlying business.
- Legacy concentration risk: Legacy brands remain overweight in the revenue mix, mostly in Class-B and Class-C towns. New product contribution is rising but the company is still working toward a balance between volume-driving legacy products and higher-growth new molecules.
- Top brands stalled: Key brands were flat or grew only 3-4% in the quarter, and that directly determines the company's headline growth rate.
- Indocap P line extension: A combination of Indomethacin and Paracetamol launched about six months ago as a line extension for the largest brand.
- New launch philosophy is anti-commodity: Management will not enter crowded categories like GLP-1 on patent-expiry day when 80 players pile in. New launches target difficult categories requiring concept selling: slower buildup but more sustainable.
Manish Gupta: "We do not intend to launch like a GLP-1 on the date of patent expiry because we know 80-guys will be there on day-one. So, our new product launches are always going to be in more difficult categories where we have to do concept selling, therefore the buildup will be slower but more sustainable."
Yash Pharma Integration
- Integration delivered: The acquired business is now the faster-growing segment within Jagsonpal. Profitability, which was roughly half of JPL's level at acquisition, has been brought up to parity. Working capital has not increased despite the acquisition.
- Gross margin runway: Gross margins are tracking well with some improvement, but more scope remains, particularly from the Yash Pharma portfolio. Management described it as a journey.
- Intangible amortisation: The intangible asset created from the ₹95 crore deal (₹88-89 crores) is depreciated annually, accounting for the decline from ₹89 crores to ₹81 crores on the balance sheet.
- Capability proof for future deals: The successful integration has given management greater confidence to pursue larger acquisitions than it would have previously.
Manish Gupta: "Today it gives me greater confidence to go and acquire something going forward and taking a bigger step compared to what I would have done earlier, because it was not about me, it is about the JPL capability."
MR Productivity & the Operating Leverage Thesis
- The paradox: Profitability is where it is despite low MR productivity. Fixed costs are already sunk, so any sales growth that outpaces the market will generate disproportionately high profit accretion compared with growth driven by expanding the field force.
- New COO as catalyst: Amrut Medhekar, with over 30 years in sales and marketing at Wockhardt, Zydus, Ranbaxy, Torrent and most recently as CEO at Akums, has been brought in to rebuild and refine strategy. Management sees his joining as the potential missing link in getting MR productivity right.
- No metric yet: When asked for a specific productivity target or timeline, management offered context about the portfolio mix challenge but did not commit to a measurable metric.
Manish Gupta: "Our profitability is where it is in spite of low MR productivity. So, therefore, as the sales grow faster than the marketplace, the accretive value creation or profitability impact will be much higher for us vis-a-vis growth, which would have come from enhanced MR numbers."
M&A Appetite & Capital Allocation
- More aggressive, within limits: Management expects Jagsonpal to be more aggressive on acquisitions than in the past, but not at Torrent's scale. The company is not big enough to absorb a large mistake.
- Funding capacity: The war chest comprises ~₹150 crores of cash, ~₹15 crores of quarterly generation, balance-sheet leverage, and shareholder backing including potential equity.
- Chronic segment on the table: The company is open to inorganic moves outside its current sub-chronic focus, including the chronic segment, despite management's stated aversion to building there organically because of doctor-gratification practices.
- ROCE dilution acknowledged: Any acquisition will tend to pull down ROCE.
Manish Gupta: "I will definitely expect Jagsonpal to be more aggressive, but certainly, it is not feasible for us to be as aggressive as Torrent in terms of the value and all whose scale is so different now, that a small mistake will not cost them the Company. In our case, we are not big enough to take a big mistake."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue growth | Targeting ~10% overall for the year; low double-digit for the remainder | FY26 |
| H2 performance | Stronger second half now that GST transition is behind | H2 FY26 |
| Medium-term growth | ~10% growth as an organisation, with acceleration thereafter | Medium-term |
| Aspirational growth plan | Management to share more detailed strategic plans | "A couple of weeks" from call date |
| New product launches | Launches planned for the rest of the year; details only at launch | FY26 |
| M&A posture | More aggressive than the past; open to chronic and beyond current sub-chronic focus | Ongoing |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹74.5 cr, flat YoY due to GST transition impact |
| H1 FY26 revenue | ₹150 cr, +10% YoY |
| EBITDA | ₹18.1 cr, margin 24.3% |
| H1 FY26 EBITDA | ₹33.8 cr, +9% YoY, margin 22.5% |
| PAT | ₹12.6 cr, +10% YoY, margin close to 17%, up 150 bps |
| H1 FY26 PAT growth | ~39% YoY |
| Cash balance | ₹160.4 cr, maintained vs June despite ₹16.7 cr dividend payout |
| Dividend paid | ₹16.7 cr, 125% or ₹2.5 per share |
| FY26 revenue growth target | ~10% for the full year, low double-digit for H2 |
| Indian pharma market growth | ~7.5% in Q2 FY26, driven by price and new launches |
| Jagsonpal's therapy-area market growth | 2.5% to 3% during the quarter |
| Top 5 brands growth | 3% to 4% for some, flattish for others |
| Brands in ₹50 cr club | 1 brand, Indocap group, in early 50s |
| MR count | ~1,000 across four divisions |
| MR attrition rate | ~30% |